Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Forms India Sales Subsidiary; Gains Positive U.S. FDA Recommendation For Telavancin

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Astellas is gearing up to launch its immunosuppressant Prograf in India in 2009 as a first-hand stab at penetrating into the Indian market with the Nov. 14 founding of its subsidiary, Astellas Pharma India Private Ltd. in Mumbai

You may also be interested in...

Astellas’ Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication

Astellas has withdrawn its application to market Vibative (telavancin) for adult complicated skin and soft tissue infections in Europe, but plans to submit a new application in 2009 that includes an indication for hospital-acquired pneumonia

Astellas Launches Graceptor In Japan

Astellas announced it launched a once-daily capsule of immunosuppressant Graceptor (tacrolimus) Oct. 28 in Japan. The modified release drug uses the same ingredient as twice-daily Prograf. As patent protection for Astellas' blockbuster drug Prograf is to expire by December 2010, the company launched the modified release version to maximum profits. Graceptor is currently available in 19 countries, and is sold under the name Advagraf in Germany. An approval application in the U.S. is delayed as U.S. FDA requested the company to submit additional data to show efficacy. (Click here for more - Japanese language

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts